company-header-background

Screen Shot 2020-04-29 at 12.11.06 AM

Lipid Nanoparticles (LNP) are the Most Clinically Advanced Non-Viral Delivery Technology 

aaaaaaaaaaaaa
Screen Shot 2020-04-29 at 12.22.09 AM

Screen Shot 2020-04-29 at 12.11.19 AM
Overview
GenVoy-ILM™ is an ionizable lipid mix that enables the rapid and easy production of RNA-loaded lipid nanoparticles (LNPs) using the NanoAssemblr®Platform.  GenVoy-ILM is the simplest way to get started with LNPs - the most advanced non-viral technology for delivering nucleic acids.

An exclusive ionizable cationic lipid mix for preclinical development:

  • • Gene Therapy
  • • Cell Therapy
  • • Vaccine

 

With applications in oncology, rare diseases, and infectious diseases.

LNPs mimic low-density lipoproteins and are taken up through an endogenous pathway where they are designed to trigger the release of nucleic acids in the cytoplasm.

Endogenous Uptake
Screen Shot 2019-06-21 at 2.58.04 PM

Deliver mRNA for gene expression


A single injection of GenVoy-ILM Factor VII siRNA-LNP was administered to mice via the tail vein at the RNA doses indicated and plasma levels of Factor VII protein were measured up to 21 days post-administration.
000000000

 

 


Screen Shot 2020-04-29 at 12.39.25 AM
Screen Shot 2020-04-29 at 12.39.40 AM
Screen Shot 2020-04-29 at 12.40.06 AM
Lipid Nanoparticles

LNPs contain a pH-sensitive ionizable cationic lipid that attract anionic nucleic acids to form the core of self-assembling nanoparticle to ensure high encapsulation.

 

At physiological pH, LNPs are neutral, eliminating a mechanism of toxicity seen with permanently cationic molecules.

 

These same pH-sensitive lipids are responsible for responding to the acidic environment of the endosome and triggering the disruption of the endosome and release of the nucleic acid into the cell.

Nucleic Acid Lipid Nanoparticle

Both The Chemistry And The Process Determine The Outcome

 

LNPs made with the NanoAssemblr®Platform have a unique homogeneous structure that is more effective compared to other methods of manufacture such as T-tube mixing. 



Use Genvoy-ILM for: 

  • • Gene silencing 
  • • Gene expression 
  • • Gene editing 
  • • Gene modulation 

Use GenVoy-ILM to encapsulate and deliver RNA: 

  • • siRNA 
  • • miRNA 
  • • tRNA 
  • • gRNA 
  • • mRNA 
00000000000
Screen Shot 2020-04-29 at 12.11.38 AM
Screen Shot 2020-04-29 at 12.12.10 AM

Product Information


User Guide

GenVoy-ILM is a pre-blended lipid mix in ethanol and is available in two formats with or without added dye for visualization.

 

• 2 mL

• 5 mL

GenVoy-ILM Vials

The Chemistry And The Process Affect The Outcome 

LNPs made with the NanoAssemblr platform exhibit a unique homogeneous core structure with exceptionally consistent size within and between batches, which has been shown to be more potent than particles made by other methods. 

 

 

 

 


Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Summary

July 13, 2017

Cell

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

J.M. Richner, B.W. Jagger, C. Shan, C.R. Fontes, K.A. Dowd, B. Cao, S. Himansu, E.A. Caine, B.T. Nunes, D.B. Medeiros a...

Read More 阅读更多

Publication - Abstract

November 01, 2018

Neuron

Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

B. Dejanovic, M.A. Huntley, A. De Mazière, W.J. Meilandt, T. Wu, K. Srinivasan and M. Sheng et al.

Read More 阅读更多

Video

November 30, 2016

“Targeted Lipid/Peptide Nanocomplexes for Nucleic Acid Delivery” - Stephen Hart, UCL

Read More 阅读更多

Publication - Abstract

May 31, 2019

Vaccine

mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerated in Healthy Adults ...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith, Ö. Almarsson, H.S. Pujar, M....

Read More 阅读更多

Publication - Summary

January 17, 2017

Proceedings of the National Academy of Sciences

Systemic Delivery of Factor IX Messenger RNA for Protein Replacement Therapy

S. Ramaswamy, N. Tonnu, K. Tachikawa, P. Limphong, J.B. Vega, P.P. Karmali, P. Chivukula, and I.M. Verma

Read More 阅读更多

Video

August 04, 2017

Ocular Delivery of mRNA - Patrick Baumhof, CureVac AG

Read More 阅读更多
Resource Center 资源中心

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.

MENU
菜单
X
X